

This infographic is not intended for use in the US, UK or Canada.

RealGiDo: REAL-WORLD STUDY ON AFATINIB DOSE ADJUSTMENT IN PATIENTS WITH EGFR MUTATION (M+) POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)



**Giotrif® (afatinib) dose adjustment:
A real-world study based on medical chart review**

RealGiDo¹

RealGiDo, a real-world, global study across 13 countries, showed that **dose adjustment is effective to help manage side effects, without compromising efficacy**

Real-world data complement randomised clinical trials and provide evidence on outcomes observed in routine clinical practice.

RealGiDo confirms findings from our clinical trials.



Canada, USA, Mexico, Austria, France, Germany, Italy, Poland, Spain, Japan, South Korea, Singapore and Taiwan



RealGiDo and LUX-Lung 3^{1,2}

Fewer side effects were observed than in LUX-Lung 3

This might be due to increased familiarity with adverse event management

RealGiDo: Dosing^{1,2}

1/3 of patients started with a dose ≤ 30 mg and had less severe side effects



RealGiDo: Time on Treatment¹

Time on treatment was 18.7 months

Time on treatment was not affected by starting dose or dose modification

1. Halmos B et al. Real-world dose adjustment study of first-line afatinib in pts with EGFR mutation-positive (EGFRm+) advanced NSCLC. Abstract accepted 2018 American Society of Clinical Oncology June 1-5, 2018, Chicago, Illinois.
2. Sequist LV et al. Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations. Journal of Clinical Oncology 2013 31:27, 3327-3334.